CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea
· Delayed Price · Currency is KRW 8,030.00
-100.00 (-1.23%)
At close: Apr 28, 2026
CJ Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3,693 | 3,467 | 5,575 | 4,075 | 4,363 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 3,693 | 3,467 | 5,575 | 4,075 | 4,363 | Upgrade
|
| Revenue Growth (YoY) | 6.52% | -37.82% | 36.82% | -6.61% | -17.86% | Upgrade
|
| Cost of Revenue | 3,060 | 3,182 | 3,802 | 2,763 | 2,721 | Upgrade
|
| Gross Profit | 632.96 | 284.83 | 1,773 | 1,311 | 1,642 | Upgrade
|
| Selling, General & Admin | 5,930 | 9,668 | 9,371 | 12,970 | 5,934 | Upgrade
|
| Research & Development | 18,051 | 23,167 | 22,823 | 19,186 | 4,852 | Upgrade
|
| Amortization of Goodwill & Intangibles | 14.06 | 15.38 | 17.24 | 33.18 | 29.06 | Upgrade
|
| Other Operating Expenses | 189.74 | 221.72 | 203.41 | 111.59 | 77.13 | Upgrade
|
| Operating Expenses | 25,419 | 34,526 | 33,829 | 34,545 | 11,750 | Upgrade
|
| Operating Income | -24,786 | -34,241 | -32,057 | -33,233 | -10,108 | Upgrade
|
| Interest Expense | -540.18 | -587.41 | -922.05 | -2,763 | -4,968 | Upgrade
|
| Interest & Investment Income | 1,935 | 1,913 | 1,367 | 1,331 | 410.15 | Upgrade
|
| Earnings From Equity Investments | - | - | 75.66 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 15.04 | -68.27 | -39.39 | 12.64 | 2.91 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.99 | 134.84 | 19.86 | 129.82 | -2,485 | Upgrade
|
| EBT Excluding Unusual Items | -23,366 | -32,849 | -31,555 | -34,523 | -17,148 | Upgrade
|
| Gain (Loss) on Sale of Assets | -638.74 | 10.89 | 8,642 | -390.7 | 10.43 | Upgrade
|
| Asset Writedown | - | - | - | - | -170.67 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1,964 | Upgrade
|
| Pretax Income | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 | Upgrade
|
| Net Income | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 | Upgrade
|
| Net Income to Common | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 | Upgrade
|
| Shares Outstanding (Basic) | 13 | 9 | 7 | 6 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 9 | 7 | 6 | 4 | Upgrade
|
| Shares Change (YoY) | 40.91% | 30.92% | 20.52% | 38.23% | 10.14% | Upgrade
|
| EPS (Basic) | -1837.00 | -3541.00 | -3234.63 | -5940.02 | -4532.31 | Upgrade
|
| EPS (Diluted) | -1837.00 | -3541.00 | -3235.00 | -5940.02 | -4533.00 | Upgrade
|
| Free Cash Flow | -23,427 | -28,138 | -29,823 | -25,108 | -9,390 | Upgrade
|
| Free Cash Flow Per Share | -1792.77 | -3034.18 | -4210.07 | -4271.74 | -2208.24 | Upgrade
|
| Gross Margin | 17.14% | 8.22% | 31.80% | 32.19% | 37.62% | Upgrade
|
| Operating Margin | -671.24% | -987.76% | -575.00% | -815.61% | -231.68% | Upgrade
|
| Profit Margin | -650.10% | -947.28% | -410.99% | -856.84% | -441.72% | Upgrade
|
| Free Cash Flow Margin | -634.44% | -811.70% | -534.93% | -616.19% | -215.22% | Upgrade
|
| EBITDA | -20,773 | -29,920 | -26,911 | -29,333 | -8,546 | Upgrade
|
| EBITDA Margin | - | - | - | - | -195.88% | Upgrade
|
| D&A For EBITDA | 4,013 | 4,321 | 5,146 | 3,900 | 1,562 | Upgrade
|
| EBIT | -24,786 | -34,241 | -32,057 | -33,233 | -10,108 | Upgrade
|
| EBIT Margin | - | - | - | - | -231.67% | Upgrade
|
| Advertising Expenses | 127.07 | 123.79 | 160.85 | 131.39 | 58.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.